LSE:AZNPharmaceuticals
AstraZeneca COPD Breakthrough With Tozorakimab Adds Fresh Upside Question
AstraZeneca's COPD drug tozorakimab reported positive Phase III results in the OBERON and TITANIA trials.
The investigational biologic is the first IL-33-targeting therapy to show efficacy in reducing COPD exacerbations.
The data mark a potential advance for patients with chronic obstructive pulmonary disease, a condition with high unmet need.
AstraZeneca (LSE:AZN), currently trading around £143.02, has been supported by a strong multi year share price run, with a 1 year return of 27.5%...